Clinical trials: pMMR
Endometrial Cancer, Recurrent Endometrial Carcinoma
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
The goal of this study is listed below. Part A (Safety Run-in Phase) : To determine feasibility of pembrolizumab and nesuparib combination as maintenance therapy in patients with MMR-proficient advanced and recurrent endometrial…
- Conditions
- Endometrial Cancer, Recurrent Endometrial Carcinoma, Endometrial Carcinoma, Gynecologycal Cancer
- Trial name
- PENELOPE (NCT06502743)
- Testing
- Nesuparib, Pembrolizumab
- Where
- 6 sites in South Korea
- Volunteers
- 92 people
- Sponsor
- Yonsei University
pMMR/MSS, Locally Advanced Rectal Carcinoma
16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer
Although standard neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC) effectively reduces local recurrence, radiotherapy-related toxicities and surgical complications severely impair patients' quality…
- Conditions
- pMMR/MSS, Locally Advanced Rectal Carcinoma, Fasting, Intermittent
- Trial name
- NCT07779694
- Testing
- 16-Hour Fasting, Serplulimab + chemotherapy
- Volunteers
- 51 people
- Sponsor
- Zhejiang University
Tislelizumab, Bevacizumab
XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
The goal of this clinical trial is to compare XELOX +Bev +Tislelizumab with standard chemotherapy，in MSS/pMMR-type RAS-mutated metastatic colorectal adenocarcinoma.
- Conditions
- Tislelizumab, Bevacizumab, Oxaliplatin, Capecitabine
- Trial name
- NCT05970302
- Testing
- Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Anal Squamous Cell Carcinoma, Colorectal Neoplasms
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-stage, phase II trial to evaluate the efficacy and safety of regorafenib in combination with tislelizumab (referred as Rego-Tisle) in adult patients with…
- Conditions
- Anal Squamous Cell Carcinoma, Colorectal Neoplasms, Soft Tissue Sarcoma, Malignant Pleural Mesothelioma
- Trial name
- REFIT-MSS (NCT05582031)
- Testing
- Regorafenib in combination with Tislelizumab
- Sponsor
- Translational Research in Oncology
Locally Advanced Rectal Cancer
Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer
This is a randomized, double-blind, controlled, Phase III clinical study to evaluate the efficacy and safety of sintilimab combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy…
- Trial name
- NCT07917468
- Testing
- Oxaliplatin, radiotherapy, Capecitabine
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer
Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer
There are several basic findings in the previous studies: The levels of renin and aldosterone in the blood of cancer patients vary greatly among individuals, and the baseline levels of some patients are relatively higher than…
- Trial name
- EAPPA (NCT06992024)
- Testing
- Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
This phase II study is a prospective, multi-center, double-blinded, and randomized trial to compare the efficacy and safety of perioperative SOX plus serplulimab with SOX plus placebo for locally advanced gastric adenocarcinoma…
- Conditions
- Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair
- Trial name
- NCT05872685
- Testing
- S1, Oxaliplatin, Serplulimab
- Where
- 5 sites in China
- Volunteers
- 314 people
- Sponsor
- Yu jiren
Early Rectal Cancer, Stage I Rectal Cancer
RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer
This is a multi-site, prospective, non-randomized phase 2 study evaluating neoadjuvant botensilimab in combination with balstilimab for patients with microsatellite stable (MSS) / mismatch repair proficient (MMRp) early rectal…
- Conditions
- Early Rectal Cancer, Stage I Rectal Cancer, Microsatellite Stable Rectal Carcinoma
- Trial name
- RECTIFY-1 (NCT07735624)
- Testing
- Botensilimab, Balstilimab
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dana-Farber Cancer Institute
Colon Cancer
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
The goal of this clinical trial is to evaluate the efficacy and safety of conversion therapy using radiotherapy combined with systemic treatment (chemotherapy + immune checkpoint inhibitors) for patients with pMMR/MSS T4M0 stage…
- Trial name
- NCT06949111
- Testing
- radiotherapy, CAPOX, Capecitabine
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Hebei Medical University Fourth Hospital
Colon Cancer
Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer
This is a research study to test whether two immunotherapy drugs-cemiplimab and fianlimab-can safely and effectively shrink colon tumors before surgery in people with stage II-III colon cancer that has not spread to other parts…
- Trial name
- NACho (NCT07224022)
- Testing
- Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
- Volunteers
- 24 people
- Sponsor
- John Strickler, M.D.
Advanced or Recurrent Endometrial Cancer
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain
This is a phase IIIb, interventional, single arm, multicentre study assessing the safety profile of durvalumab in combination with carboplatin-paclitaxel chemotherapy followed by durvalumab with olaparib as first-line treatment…
- Trial name
- DUoENDE (NCT06746116)
- Testing
- Durvalumab + Chemotherapy phase, Durvalumab + Olaparib phase
- Where
- 24 sites in Spain
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Locally Advanced Rectal Cancer
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
This is an open, prospective, multi-center, single-arm phase II clinical study assessing the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin in patients with pMMR/MSS locally…
- Trial name
- NCT06056804
- Testing
- capecitabine, tislelizumab, thymalfasin
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Colorectal Adenocarcinoma, Mucinous Adenocarcinoma
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
Hypothesis: Patients with metastatic colorectal cancer with DNA mismatch repair-proficient (pMMR) function / microsatellite-stable (MSS) phenotype harbor a non-immunogenic disease that can be transformed into an immunogenic…
- Conditions
- Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma
- Trial name
- METIMMOX-2 (NCT05504252)
- Testing
- Nivolumab, Oxaliplatin
- Where
- 3 sites in Norway
- Volunteers
- 80 people
- Sponsor
- University Hospital, Akershus
Rectal Cancer
Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer
The objective is to evaluate whether the neoadjuvant combination of PD-1 inhibitor tislelizumab and interleukin-2 (IL-2) can significantly enhance the complete response rate (cCR + local excision pCR) and organ preservation rate…
- Trial name
- NCT06504875
- Testing
- Tislelizumab, Interleukin-2, Capecitabine
- Volunteers
- 23 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with…
- Trial name
- NCT07198074
- Testing
- Bevacizumab, Biospecimen Collection, Carboplatin
- Where
- 306 sites in United States
- Volunteers
- 255 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Adenocarcinoma, Esophagogastric Juction Cancer
Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer
Background: Gastric cancer remains a significant health burden globally, particularly in China, where the majority of patients present with advanced disease at diagnosis.
- Conditions
- Gastric Adenocarcinoma, Esophagogastric Juction Cancer, Proficient Mismatch Repair
- Trial name
- NCT07621562
- Testing
- Tafolecimab plus Sintilimab combined with SOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Rectal Cancer
Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of combining DCSZ11 with radiation and capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with mismatch repair proficient (pMMR)…
- Trial name
- NCT07580339
- Testing
- DCSZ11, Radiation, Capecitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rectal Cancer, Neoadjuvant Therapies
Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)
The goal of this clinical trial is to evaluate whether a total neoadjuvant therapy (TNT) regimen combining long-course chemoradiotherapy, sequential chemotherapy, and PD-1 inhibitor can improve response rates, enhance…
- Conditions
- Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
- Trial name
- NCT06923345
- Testing
- Reduced CTV, Conventional CTV
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer Liver Metastases
Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases
This prospective, single-arm study aims to investigate the safety and efficacy of Nivolumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS Colorectal cancer liver metastases patients
- Trial name
- NCT05588297
- Testing
- CapOx(Capecitabine+ Oxaliplatin), Bevacizumab, Nivolumab
- Volunteers
- 12 people
- Sponsor
- Shanghai Changzheng Hospital
Colon Cancer, Immunotherapy
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
To compare the efficacy and safety of tirellizumab combined with anlotinib in the treatment of mss colorectal cancer. To investigate the effective biomarker of anlotinib combined with tiralizumab
- Trial name
- NCT06573424
- Testing
- Tislelizumab+anlotinib, anlotinib
- Where
- China
- Volunteers
- 124 people
- Sponsor
- fan li